BioMarin sees ~$283M Q3 IPR&D charge from Alesta deal, $1.50 hit to GAAP and non-GAAP EPS

BIOMARIN PHARMACEUTICAL INC

BioMarin expects ~$283M of pre-tax acquired IPR&D expense in Q3 2026 tied to the Alesta Therapeutics B.V. acquisition, completed August 31, 2026.
The Q3 charge plus ongoing operating expenses cut about $1.50 from both GAAP diluted EPS and Non-GAAP Diluted EPS for the third quarter of 2026.
Full-year 2026 pre-tax charges expected at ~$320M, including transaction and transition costs, an unfavorable ~$1.55 impact to both GAAP and Non-GAAP Diluted EPS.
BioMarin's previously announced August 6, 2026 full-year 2026 guidance did not reflect Alesta; updated FY2026 guidance will come with Q3 2026 results.
Results for the quarter ended September 30, 2026 are not finalized and remain subject to BioMarin's financial statement closing procedures.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.